Aldoss Ibrahim, Pullarkat Vinod, Stein Anthony S
Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA, USA.
Gehr Family Center for Leukemia Research, City of Hope, 1500 Duarte Road, Duarte, CA 91010, USA.
Ther Adv Hematol. 2021 Feb 11;12:2040620720986646. doi: 10.1177/2040620720986646. eCollection 2021.
Venetoclax in combination with hypomethylating agents (HMAs) or low-dose cytarabine (LDAC) has demonstrated exceptional activity in elderly and unfit patients with newly diagnosed acute myeloid leukemia (AML). Notably, the safety profile of venetoclax-based induction regimens was favorable, with a low rate of early treatment-related mortality, even in frail study participants. Thus, the introduction of venetoclax has transformed the landscape of AML therapy in elderly patients. Given these promising results, venetoclax in combination with other agents is now being studied as a frontline therapy in younger patients with AML, as well as in relapsed/refractory AML patients. Here, we review clinical data for venetoclax-based therapy in AML, both from prospective as well as retrospective studies, and highlight ongoing novel studies of venetoclax-containing regimens and discuss future research directions.
维奈克拉联合低甲基化药物（HMAs）或小剂量阿糖胞苷（LDAC）在新诊断的老年及身体状况不佳的急性髓系白血病（AML）患者中已显示出卓越的活性。值得注意的是，基于维奈克拉的诱导方案安全性良好，早期治疗相关死亡率较低，即使在身体虚弱的研究参与者中也是如此。因此，维奈克拉的引入改变了老年AML患者的治疗格局。鉴于这些令人鼓舞的结果，维奈克拉联合其他药物目前正在作为年轻AML患者以及复发/难治性AML患者的一线治疗进行研究。在此，我们回顾了基于维奈克拉治疗AML的临床数据，包括前瞻性研究和回顾性研究的数据，并重点介绍了正在进行的含维奈克拉方案的新研究，同时讨论未来的研究方向。
